Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

Drug-Coated Balloons Unveiled, a Radcliffe Cardiology Podcast Series.

Bridging science and application with already 27 000+ listens.‡

This podcast is financially sponsored by Medtronic.

Alert Indications, Safety, and Warnings

Explore the transformative world of Drug-Coated Balloons (DCBs) in interventional cardiology with renowned experts through an exclusive Podcast series.

In this podcast series specifically designed for interventional cardiologists, you will delve into the origins and science behind drug-coated balloons (DCBs), review important clinical data, and explore evolving treatments. 

Join Dr. Rasha Al-Lamee for engaging conversations with leading experts in interventional cardiology.

This podcast is hosted by Radcliffe Cardiology and independently supported by Medtronic. Please note this content is intended for healthcare professionals.

Icon
Episode 1: explore origins of DCB

Gain unique insights from Dr. Rasha Al-Lamee and Prof. Bruno Scheller as they unfold the fascinating story of DCBs, and explore how these innovations have transformed the field of Cardiology. 10 min 38 sec

Radcliffe | Apple | Spotify | Soundcloud

Icon
Episode 2: science behind DCB 

Join Dr. R. Al-Lamee, and Dr. S. Tunev and gain valuable perspective about DCB’s advanced technology, their primary role in interventional cardiology, the ideal DCBs characteristics and the importance of the excipient. 13 min 35 sec 

Radcliffe | Apple | Spotify | Soundcloud

Prevail™ paclitaxel-coated PTCA balloon catheter on a conceptual purple background with particles.
Prevail™ DCB has the broadest range of CE Mark indications†,1,2

Prevail™ DCB meets the needs of a complex PCI practice with new indications.† It’s the only DCB indicated for treatment of multivessel disease, acute coronary syndrome, and diabetic patients.

View the CE Mark summary
Icon
Episode 3: DCB vs DES vs POBA 

Join Dr. R. Al-Lamee, and Dr. Azeem Latib as they shed light on the importance of personalized treatment approaches when considering DCBs, Drug-Eluting Stent (DES), and Plain Old Balloon Angioplasty (POBA).  13 min 25 sec 

Radcliffe | Apple | Spotify | Soundcloud

Icon
Episode 4: leaving nothing behind 

Join Dr R. Al-Lamee and Dr Simon Eccleshall as they discuss the pros and cons of the 'leaving nothing behind' strategy and discover when DCB can be advantageous in clinical practice. 14 min 25 sec 
 

Radcliffe | Apple | Spotify | Soundcloud

Prevail™ paclitaxel-coated PTCA balloon catheter drug deliverability illustration.
Successful drug delivery3,4

The coating process of the balloon ensures a uniform drug distribution5 with up to 65% of the drug protected within the folds.6

Watch the animation

Stream the podcast series on your favorite platform now

Back to top

Request more information about Prevail™ drug-coated balloon.

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

† Prevail™ DCB expanded indications are approved in EU and UK.

‡ Source Radcliffe group - July 2025

References

1

Medtronic data on file

2

Information comes from key competitive DCB IFUs, or the respective websites accessed in May 2025.

3

Based on internal report (D00178518_A), Elution evaluation of the Medtronic drug-coated IN.PACT™ Euphora™ balloon in a porcine artery model. 2019.

4

Based on internal report (D00655639_Rev.A), Prevail™ by Medtronic versus SeQuent®* Please Neo by B. Braun coronary drug-coated balloons (DCB) drug “wash-off” study. 2022.

5

Based on internal report (RE-10034), IN.PACT™ Admiral™ verification of coating process optimization. 2019.

6

Based on internal report (D00277875_A), Position paper to measure the percentage of the balloon folds that are ‘internal’ versus ‘external’ for the 3-fold and 5-fold Prevail™ DCBs. 2020.

This podcast is financially sponsored by Medtronic. The content has been provided by the participants. The positions and opinions of the participants are based on their professional clinical judgement. Medtronic does not take a position on matters of clinical practice, outside the scope of the safe and effective use of its products.

For distribution only in markets where the Prevail™ drug-coated balloon has been approved. Not for distribution in the USA, Japan, Canada, France and Brazil. Prevail™ DCB expanded indications are approved in EU and UK.